uniQure N.V. - Ordinary Shares (QURE)

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130.

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.

uniQure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan Drug statuses.

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four.

The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.

uniQure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.

QURE stock results show that uniQure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

UniQure N.V. (NASDAQ: QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's disease.